Brokerages expect that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will announce ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.21) to ($0.19). Infinity Pharmaceuticals reported earnings of ($0.34) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.2%. The firm is expected to announce its next earnings results on Thursday, August 2nd.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.74) per share for the current financial year, with EPS estimates ranging from ($0.77) to ($0.71). For the next fiscal year, analysts forecast that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.88) to ($0.59). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Infinity Pharmaceuticals.
Get Infinity Pharmaceuticals alerts:
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18).
Separately, Zacks Investment Research downgraded Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday.
In other news, major shareholder Value Fund L. P. Biotechnology purchased 1,510,000 shares of the company’s stock in a transaction dated Tuesday, April 10th. The shares were purchased at an average price of $1.97 per share, with a total value of $2,974,700.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 11.45% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in shares of Infinity Pharmaceuticals during the 3rd quarter valued at $135,000. Alambic Investment Management L.P. purchased a new position in shares of Infinity Pharmaceuticals during the 4th quarter valued at $158,000. Wells Fargo & Company MN lifted its position in shares of Infinity Pharmaceuticals by 654.7% during the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 91,206 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Infinity Pharmaceuticals by 102.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 75,980 shares during the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of Infinity Pharmaceuticals during the 4th quarter valued at $312,000. 47.35% of the stock is currently owned by hedge funds and other institutional investors.
Infinity Pharmaceuticals remained flat at $$1.99 during trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 369,500 shares, compared to its average volume of 677,495. The company has a market cap of $116.63 million, a P/E ratio of -2.40 and a beta of 2.50. Infinity Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.75.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com